Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
17.32
-0.06 (-0.35%)
At close: Nov 28, 2025, 1:00 PM EST
17.14
-0.18 (-1.01%)
After-hours: Nov 28, 2025, 4:42 PM EST
Xencor Employees
Xencor had 250 employees as of December 31, 2024. The number of employees decreased by 30 or -10.71% compared to the previous year.
Employees
250
Change (1Y)
-30
Growth (1Y)
-10.71%
Revenue / Employee
$600,528
Profits / Employee
-$523,292
Market Cap
1.24B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 250 | -30 | -10.71% |
| Dec 31, 2023 | 280 | -1 | -0.36% |
| Dec 31, 2022 | 281 | 27 | 10.63% |
| Dec 31, 2021 | 254 | 52 | 25.74% |
| Dec 31, 2020 | 202 | 36 | 21.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
XNCR News
- 19 days ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 24 days ago - Xencor Reports Third Quarter 2025 Financial Results - Business Wire
- 5 weeks ago - Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript - Seeking Alpha
- 5 weeks ago - Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma - Business Wire
- 5 weeks ago - Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - Business Wire
- 6 weeks ago - Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Business Wire
- 2 months ago - Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release - Seeking Alpha
- 4 months ago - Xencor (XNCR) Q2 Revenue Jumps 82% - The Motley Fool